Venetoclax combinations in mutant AML subtypes podcast: FLT3 - a podcast by Scientific Education Support

During the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, the AML Hub spoke to Naval Daver, MD Anderson Cancer Center, Houston, US, about venetoclax combinations in patients with FLT3-mutated AML.

Emerging data on venetoclax combinations in patients with FLT3-mutated AML have been presented at ASH 2020. FLT3 mutations are the most common mutations in patients with AML.

In this podcast, Daver discusses the results of a study comparing the combination of azacitidine plus venetoclax versus azacitidine plus placebo in patients with FLT3-mutated AML. He also talks about a study evaluating the combination of gilteritinib with venetoclax in patients with relapsed/refractory FLT3-mutated AML and reports the results of the first combination of decitabine + venetoclax + FLT3 inhibitor of clinician’s choice in patients with FLT3-mutated AML.

---

See acast.com/privacy for privacy and opt-out information.

Further episodes of AML Hub

Further podcasts by Scientific Education Support

Website of Scientific Education Support